thalidomide has been researched along with Telangiectasia, Hereditary Hemorrhagic in 29 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Telangiectasia, Hereditary Hemorrhagic: An autosomal dominant vascular anomaly characterized by telangiectases of the skin and mucous membranes and by recurrent gastrointestinal bleeding. This disorder is caused by mutations of a gene (on chromosome 9q3) which encodes endoglin, a membrane glycoprotein that binds TRANSFORMING GROWTH FACTOR BETA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Low-dose thalidomide seems to be safe and effective for the reduction of epistaxis in patients with hereditary haemorrhagic telangiectasia." | 9.20 | Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study. ( Balduini, CL; Bastia, R; Bellistri, F; Benazzo, M; Chu, F; Danesino, C; Grignani, P; Invernizzi, R; Klersy, C; Matti, E; Olivieri, C; Ornati, F; Pagella, F; Plumitallo, S; Quaglia, F; Spinozzi, G, 2015) |
| " Thalidomide has been used as a therapeutic strategy for refractory epistaxis in hereditary haemorrhagic telangiectasia patients." | 8.98 | The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review. ( Harrison, L; Jervis, P; Kundra, A, 2018) |
| "To evaluate the effectiveness of thalidomide for epistaxis in hereditary hemorrhagic telangiectasia (HHT), 7 HHT patients with recurrent epistaxis were treated with thalidomide at an initial dose of 50 mg/d, gradually increasing to 100 mg/d if needed." | 8.95 | Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study. ( Chen, X; Fang, J; Guan, J; Su, K; Ye, H; Zhang, W; Zhu, B, 2017) |
| " 67 received thalidomide, all for epistaxis and/or gastrointestinal bleeding; they received thalidomide for a mean of 13." | 7.91 | Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. ( Botella, LM; Buscarini, E; Dupuis-Girod, S; Geisthoff, U; Kjeldsen, AD; Mager, HJ; Pagella, F; Shovlin, CL; Suppressa, P; Zarrabeitia, R, 2019) |
| "To analyze a hereditary hemorrhagic telangiectasia(HHT) family Activin receptor-like kinase 1(ACVRL1), Endoglin (ENG) and Mothers against decapentaplegic homolog 4 (MADH4, SMAD4) gene mutation, meanwhile, to observe the curative effect of thalidomide in treatment of HHT patients." | 7.85 | [Gene Analysis of A Chinese Family with Hereditary Hemorrhagic Telangiectasia and its Curative Effect of Thalidomide]. ( Cheng, Z; Peng, HL; Yi, YF; Yu, Q, 2017) |
| "In this work nasal powder formulations of thalidomide were designed and studied to be used by persons affected by hereditary hemorrhagic telangiectasia as a complementary anti-epistaxis therapy, with the goal of sustaining the effect obtained with thalidomide oral treatment after its discontinuation for adverse effects." | 7.83 | Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia. ( Bettini, R; Bortolotti, F; Buttini, F; Chiapponi, V; Colombo, G; Colombo, P; Danesino, C; Invernizzi, R; Pagella, F; Quaglia, F; Rossi, A; Russo, P; Sonvico, F, 2016) |
| " In this report, we presented a Chinese patient with recurrent melena due to gastric angiodysplasia in HHT treated successfully with thalidomide." | 7.79 | Successful treatment of thalidomide for recurrent bleeding due to gastric angiodysplasia in hereditary hemorrhagic telangiectasia. ( Chen, Y; Du, Q; Wang, XY, 2013) |
| " We report here that treatment with thalidomide reduced the severity and frequency of nosebleeds (epistaxis) in the majority of a small group of subjects with HHT tested." | 7.76 | Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. ( Arthur, HM; Bréant, C; Disch, F; Eichmann, A; Freitas, C; Larrivée, B; Lebrin, F; Mager, JJ; Martin, S; Mathivet, T; Mummery, CL; Raymond, K; Snijder, RJ; Srun, S; Thomas, JL; van den Brink, S; Westermann, CJ, 2010) |
| "Thalidomide was recently reported to reduce the severity and frequency of epistaxes in patients with hereditary haemorrhagic telangiectasia (HHT)." | 5.37 | Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia. ( Hermans, C; Lambert, C; Penaloza, A; Vekemans, MC, 2011) |
| "Low-dose thalidomide seems to be safe and effective for the reduction of epistaxis in patients with hereditary haemorrhagic telangiectasia." | 5.20 | Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study. ( Balduini, CL; Bastia, R; Bellistri, F; Benazzo, M; Chu, F; Danesino, C; Grignani, P; Invernizzi, R; Klersy, C; Matti, E; Olivieri, C; Ornati, F; Pagella, F; Plumitallo, S; Quaglia, F; Spinozzi, G, 2015) |
| " In a few small studies, thalidomide was shown to consistently improve severity and frequency of epistaxis and improve hemoglobin concentrations while decreasing the need for transfusion." | 4.98 | Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review. ( Clark, C; Halderman, AA; Invernizzi, R; Marple, BF; Poetker, DM; Reh, DD; Ryan, MW; Sindwani, R, 2018) |
| " Thalidomide has been used as a therapeutic strategy for refractory epistaxis in hereditary haemorrhagic telangiectasia patients." | 4.98 | The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review. ( Harrison, L; Jervis, P; Kundra, A, 2018) |
| "To evaluate the effectiveness of thalidomide for epistaxis in hereditary hemorrhagic telangiectasia (HHT), 7 HHT patients with recurrent epistaxis were treated with thalidomide at an initial dose of 50 mg/d, gradually increasing to 100 mg/d if needed." | 4.95 | Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study. ( Chen, X; Fang, J; Guan, J; Su, K; Ye, H; Zhang, W; Zhu, B, 2017) |
| " 67 received thalidomide, all for epistaxis and/or gastrointestinal bleeding; they received thalidomide for a mean of 13." | 3.91 | Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. ( Botella, LM; Buscarini, E; Dupuis-Girod, S; Geisthoff, U; Kjeldsen, AD; Mager, HJ; Pagella, F; Shovlin, CL; Suppressa, P; Zarrabeitia, R, 2019) |
| "To analyze a hereditary hemorrhagic telangiectasia(HHT) family Activin receptor-like kinase 1(ACVRL1), Endoglin (ENG) and Mothers against decapentaplegic homolog 4 (MADH4, SMAD4) gene mutation, meanwhile, to observe the curative effect of thalidomide in treatment of HHT patients." | 3.85 | [Gene Analysis of A Chinese Family with Hereditary Hemorrhagic Telangiectasia and its Curative Effect of Thalidomide]. ( Cheng, Z; Peng, HL; Yi, YF; Yu, Q, 2017) |
| "In this work nasal powder formulations of thalidomide were designed and studied to be used by persons affected by hereditary hemorrhagic telangiectasia as a complementary anti-epistaxis therapy, with the goal of sustaining the effect obtained with thalidomide oral treatment after its discontinuation for adverse effects." | 3.83 | Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia. ( Bettini, R; Bortolotti, F; Buttini, F; Chiapponi, V; Colombo, G; Colombo, P; Danesino, C; Invernizzi, R; Pagella, F; Quaglia, F; Rossi, A; Russo, P; Sonvico, F, 2016) |
| "Thalidomide has shown its efficacy in the treatment of epistaxis in hereditary hemorrhagic telangiectasia (HHT) patients." | 3.79 | Pulmonary arteriovenous malformations etiologies in HHT patients and potential utility of thalidomide. ( El Hajjam, M; Lacombe, P; Lacout, A; Marcy, PY, 2013) |
| " In this report, we presented a Chinese patient with recurrent melena due to gastric angiodysplasia in HHT treated successfully with thalidomide." | 3.79 | Successful treatment of thalidomide for recurrent bleeding due to gastric angiodysplasia in hereditary hemorrhagic telangiectasia. ( Chen, Y; Du, Q; Wang, XY, 2013) |
| " We report here that treatment with thalidomide reduced the severity and frequency of nosebleeds (epistaxis) in the majority of a small group of subjects with HHT tested." | 3.76 | Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. ( Arthur, HM; Bréant, C; Disch, F; Eichmann, A; Freitas, C; Larrivée, B; Lebrin, F; Mager, JJ; Martin, S; Mathivet, T; Mummery, CL; Raymond, K; Snijder, RJ; Srun, S; Thomas, JL; van den Brink, S; Westermann, CJ, 2010) |
| "Although epistaxis is usually presented in childhood (mean age 11 ± 7." | 1.48 | Clinical features and treatment of hereditary hemorrhagic telangiectasia. ( Li, S; Wang, SJ; Zhao, YQ, 2018) |
| "Thalidomide was recently reported to reduce the severity and frequency of epistaxes in patients with hereditary haemorrhagic telangiectasia (HHT)." | 1.37 | Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia. ( Hermans, C; Lambert, C; Penaloza, A; Vekemans, MC, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (13.79) | 29.6817 |
| 2010's | 24 (82.76) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Santos, S | 1 |
| Bernardes, C | 1 |
| Borges, V | 1 |
| Ramos, G | 1 |
| Fang, J | 1 |
| Chen, X | 1 |
| Zhu, B | 1 |
| Ye, H | 1 |
| Zhang, W | 1 |
| Guan, J | 1 |
| Su, K | 1 |
| Becq, A | 1 |
| Rahmi, G | 1 |
| Perrod, G | 1 |
| Cellier, C | 1 |
| Nakamura, T | 1 |
| Ogo, T | 1 |
| Tahara, N | 1 |
| Fukui, S | 1 |
| Tsuji, A | 1 |
| Ueda, J | 1 |
| Fukumoto, Y | 1 |
| Nakanishi, N | 1 |
| Ogawa, H | 1 |
| Yasuda, S | 1 |
| Yu, Q | 1 |
| Cheng, Z | 1 |
| Yi, YF | 2 |
| Peng, HL | 2 |
| Halderman, AA | 1 |
| Ryan, MW | 1 |
| Clark, C | 1 |
| Sindwani, R | 1 |
| Reh, DD | 1 |
| Poetker, DM | 1 |
| Invernizzi, R | 3 |
| Marple, BF | 1 |
| Baysal, M | 1 |
| Ümit, EG | 1 |
| Kırkızlar, HO | 1 |
| Özdöver, AC | 1 |
| Demir, AM | 1 |
| Li, S | 1 |
| Wang, SJ | 1 |
| Zhao, YQ | 1 |
| Harrison, L | 1 |
| Kundra, A | 1 |
| Jervis, P | 1 |
| Buscarini, E | 1 |
| Botella, LM | 1 |
| Geisthoff, U | 1 |
| Kjeldsen, AD | 1 |
| Mager, HJ | 1 |
| Pagella, F | 3 |
| Suppressa, P | 1 |
| Zarrabeitia, R | 1 |
| Dupuis-Girod, S | 1 |
| Shovlin, CL | 1 |
| Abrantes, J | 1 |
| Fernandes, C | 1 |
| Vieira, CL | 1 |
| Lacout, A | 1 |
| Marcy, PY | 1 |
| El Hajjam, M | 1 |
| Lacombe, P | 1 |
| Wang, XY | 1 |
| Chen, Y | 1 |
| Du, Q | 1 |
| Xu, M | 1 |
| Hou, Y | 1 |
| Sheng, L | 1 |
| Peng, J | 1 |
| Zhou, SK | 1 |
| Xie, SS | 1 |
| Zhang, GS | 1 |
| Franchini, M | 1 |
| Lippi, G | 1 |
| Quaglia, F | 2 |
| Klersy, C | 1 |
| Ornati, F | 1 |
| Chu, F | 1 |
| Matti, E | 1 |
| Spinozzi, G | 1 |
| Plumitallo, S | 1 |
| Grignani, P | 1 |
| Olivieri, C | 1 |
| Bastia, R | 1 |
| Bellistri, F | 1 |
| Danesino, C | 2 |
| Benazzo, M | 1 |
| Balduini, CL | 1 |
| Hosman, A | 1 |
| Westermann, CJ | 2 |
| Snijder, R | 1 |
| Disch, F | 2 |
| Mummery, CL | 2 |
| Mager, JJ | 2 |
| Colombo, G | 1 |
| Bortolotti, F | 1 |
| Chiapponi, V | 1 |
| Buttini, F | 1 |
| Sonvico, F | 1 |
| Russo, P | 1 |
| Bettini, R | 1 |
| Colombo, P | 1 |
| Rossi, A | 1 |
| Bowcock, SJ | 1 |
| Patrick, HE | 1 |
| Bauditz, J | 1 |
| Lebrin, F | 1 |
| Srun, S | 1 |
| Raymond, K | 1 |
| Martin, S | 1 |
| van den Brink, S | 1 |
| Freitas, C | 1 |
| Bréant, C | 1 |
| Mathivet, T | 1 |
| Larrivée, B | 1 |
| Thomas, JL | 1 |
| Arthur, HM | 1 |
| Snijder, RJ | 1 |
| Eichmann, A | 1 |
| Akhurst, RJ | 1 |
| Nau, JY | 1 |
| Penaloza, A | 1 |
| Vekemans, MC | 1 |
| Lambert, C | 1 |
| Hermans, C | 1 |
| Chen, CH | 1 |
| Hsu, HH | 1 |
| Hu, RH | 1 |
| Lee, PH | 1 |
| Ho, CM | 1 |
| Alam, MA | 1 |
| Sami, S | 1 |
| Babu, S | 1 |
| Pérez-Encinas, M | 1 |
| Rabuñal Martínez, MJ | 1 |
| Bello López, JL | 1 |
| Kurstin, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)[NCT01485224] | Phase 2 | 31 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for thalidomide and Telangiectasia, Hereditary Hemorrhagic
| Article | Year |
|---|---|
Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study.
Topics: Adult; Aged; Epistaxis; Female; Humans; Male; Middle Aged; Severity of Illness Index; Telangiectasia | 2017 |
Hemorrhagic angiodysplasia of the digestive tract: pathogenesis, diagnosis, and management.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Argon Plasma Coagulation; Electrocoagulation; Embolization, | 2017 |
Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review.
Topics: Administration, Oral; Administration, Topical; Angiogenesis Inhibitors; Epistaxis; Estriol; Estrogen | 2018 |
The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review.
Topics: Angiogenesis Inhibitors; Epistaxis; Humans; Recurrence; Telangiectasia, Hereditary Hemorrhagic; Thal | 2018 |
Therapeutic effects of thalidomide in hematologic disorders: a review.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Graft vs Host Disease; Hematologic Neoplasms; Hum | 2013 |
[Angiogenesis inhibitors for treatment of angiodysplasia-related gastrointestinal bleeding].
Topics: Angiodysplasia; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2009 |
1 trial available for thalidomide and Telangiectasia, Hereditary Hemorrhagic
| Article | Year |
|---|---|
Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study.
Topics: Aged; Epistaxis; Female; Humans; Italy; Male; Middle Aged; Quality of Life; Telangiectasia, Heredita | 2015 |
22 other studies available for thalidomide and Telangiectasia, Hereditary Hemorrhagic
| Article | Year |
|---|---|
Gastric antral vascular ectasia (GAVE) and hereditary hemorrhagic telangiectasia (HHT): two different conditions, one treatment.
Topics: Angiogenesis Inhibitors; Argon Plasma Coagulation; Bevacizumab; Combined Modality Therapy; Erythrocy | 2020 |
Thalidomide for Hereditary Hemorrhagic Telangiectasia With Pulmonary Arterial Hypertension.
Topics: Adolescent; Adult; Blood Transfusion; Echocardiography; Electrocardiography; Fatal Outcome; Female; | 2018 |
[Gene Analysis of A Chinese Family with Hereditary Hemorrhagic Telangiectasia and its Curative Effect of Thalidomide].
Topics: Endoglin; Genetic Testing; Humans; Mutation; Pedigree; Telangiectasia, Hereditary Hemorrhagic; Thali | 2017 |
Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life
Topics: Adult; Aged; Epistaxis; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Quality of Life | 2019 |
Clinical features and treatment of hereditary hemorrhagic telangiectasia.
Topics: Adult; Angiogenesis Inhibitors; Arteriovenous Malformations; Delayed Diagnosis; Epistaxis; Female; H | 2018 |
Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia.
Topics: Adolescent; Adult; Bevacizumab; Epistaxis; Female; Hemorrhage; Humans; Male; Retrospective Studies; | 2019 |
Pulmonary arteriovenous malformation in hereditary haemorrhagic telangiectasia.
Topics: Angiogenesis Inhibitors; Argon Plasma Coagulation; Arteriovenous Malformations; Bevacizumab; Endosco | 2019 |
Pulmonary arteriovenous malformations etiologies in HHT patients and potential utility of thalidomide.
Topics: Angiogenesis Inhibitors; Arteriovenous Fistula; Humans; Models, Biological; Neovascularization, Path | 2013 |
Successful treatment of thalidomide for recurrent bleeding due to gastric angiodysplasia in hereditary hemorrhagic telangiectasia.
Topics: Aged; Angiodysplasia; Gastrointestinal Hemorrhage; Humans; Male; Recurrence; Stomach Diseases; Telan | 2013 |
Thalidomide Effects in Patients with Hereditary Hemorrhagic Telangiectasia During Therapeutic Treatment and in Fli-EGFP Transgenic Zebrafish Model.
Topics: Animals; Animals, Genetically Modified; Female; Green Fluorescent Proteins; Humans; Middle Aged; Tel | 2015 |
Thalidomide for hereditary haemorrhagic telangiectasia.
Topics: Epistaxis; Humans; Telangiectasia, Hereditary Hemorrhagic; Thalidomide | 2015 |
Follow-up of Thalidomide treatment in patients with Hereditary Haemorrhagic Telangiectasia.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Follow-Up Studies; Humans; Male; Medicatio | 2015 |
Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia.
Topics: Administration, Intranasal; Animals; beta-Cyclodextrins; Chemistry, Pharmaceutical; Drug Carriers; E | 2016 |
Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias?
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Chronic Disease; Female; Gastrointestinal Hemorrhage; | 2009 |
Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia.
Topics: Aged; Animals; Blood Vessels; Disease Models, Animal; Endothelial Cells; Epistaxis; Hemoglobins; Hum | 2010 |
Taking thalidomide out of rehab.
Topics: Animals; Endothelial Cells; Epistaxis; Humans; Mice; Neovascularization, Physiologic; Telangiectasia | 2010 |
[Thalidomide: new therapeutic indications?].
Topics: Angiogenesis Inhibitors; Humans; Leprostatic Agents; Leprosy, Lepromatous; Telangiectasia, Hereditar | 2010 |
Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia.
Topics: Activin Receptors, Type II; Contraindications; Epistaxis; Female; Humans; Middle Aged; Mutation; Tel | 2011 |
Long-term therapy with thalidomide in hereditary hemorrhagic telangiectasia: case report and literature review.
Topics: Adult; Angiogenesis Inhibitors; Female; Humans; Telangiectasia, Hereditary Hemorrhagic; Thalidomide | 2012 |
Successful treatment of bleeding gastro-intestinal angiodysplasia in hereditary haemorrhagic telangiectasia with thalidomide.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Female; Gastrointestinal Diseases; Gastrointestinal H | 2011 |
Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Electrocoagulation; Gastrointestinal Hemorrhag | 2002 |
Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease.
Topics: Abdominal Neoplasms; Aged; Angiogenesis Inhibitors; Humans; Leiomyosarcoma; Male; Telangiectasia, He | 2002 |